T
Thomas J. Ettrich
Researcher at University of Ulm
Publications - 139
Citations - 1581
Thomas J. Ettrich is an academic researcher from University of Ulm. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 17, co-authored 104 publications receiving 815 citations. Previous affiliations of Thomas J. Ettrich include Martin Luther University of Halle-Wittenberg.
Papers
More filters
Journal ArticleDOI
FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109).
Dominik Paul Modest,Uwe M. Martens,Jorge Riera-Knorrenschild,J. Greeve,Axel Florschütz,Swen Wessendorf,Thomas J. Ettrich,Stephan Kanzler,Dominik Nörenberg,Jens Ricke,Max Seidensticker,Swantje Held,Petra Buechner-Steudel,Jens Atzpodien,Heinemann,Heinemann,Thomas Seufferlein,Andrea Tannapfel,Anke Reinacher-Schick,Michael Geissler +19 more
TL;DR: The addition of panitumumab to mFOLFOXIRI in patients with RAS WT metastatic colorectal cancer improved the ORR and rate of secondary resection of metastases and represents a treatment option in selected and fit patients in need of highly active first-line therapy.
Journal ArticleDOI
A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study
Ö. Türeci,Ugur Sahin,Henning Schulze-Bergkamen,Zanete Zvirbule,Florian Lordick,Dieter Koeberle,Peter C. Thuss-Patience,Thomas J. Ettrich,Dirk Arnold,Florian Bassermann,S-E. Al-Batran,Kai Wiechen,Karl Dhaene,Daniel Maurus,M. Gold,Christoph Huber,Andrew Krivoshik,A. Arozullah,Jung Wook Park,Martin Schuler +19 more
TL;DR: Zolbetuximab monotherapy was well tolerated and exhibited antitumour activity in patients with CLDN18.2-positive advanced gastric or GEJ adenocarcinomas, with response rates similar to those reported for single-agent targeted agents in gastric/GEJ cancer trials.
Journal ArticleDOI
Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
Volker Kunzmann,Jens T. Siveke,Hana Algül,Eray Goekkurt,Gabriele Margareta Siegler,Uwe M. Martens,Dirk Waldschmidt,Uwe Pelzer,Martin Fuchs,Frank Kullmann,Stefan Boeck,Thomas J. Ettrich,Swantje Held,Ralph Keller,Ingo Klein,Christoph-Thomas Germer,Hubert J. Stein,Helmut Friess,Marcus Bahra,Ralf Jakobs,Ingo Hartlapp,Volker Heinemann,Elke Hennes,U. Lindig,Thomas Geer,Michael Stahl,Metin Senkal,Thomas Südhoff,Matthias Egger,Christoph Kahl,Christina Große-Thie,Marcel Reiser,Stefan Mahlmann,Peter Fix,Holger Schulz,Georg Maschmeyer,Wolfgang Blau +36 more
TL;DR: The primary endpoint was surgical conversion rate (complete macroscopic tumour resection) in the randomised population by intention-to-treat analysis, which was assessed by surgical exploration in all patients with at least stable disease after completion of induction chemotherapy.
Journal ArticleDOI
Genotyping of circulating tumor DNA in cholangiocarcinoma reveals diagnostic and prognostic information.
Thomas J. Ettrich,Daniel Schwerdel,Anna Dolnik,F. Beuter,Tamara J. Blätte,Stefan Schmidt,Nora Stanescu-Siegmund,Jochen Steinacker,Ralf Marienfeld,Alexander Kleger,Lars Bullinger,Thomas Seufferlein,A. W. Berger,A. W. Berger +13 more
TL;DR: The molecular landscape of CCA is accessible via ctDNA, which could be helpful to facilitate diagnosis and personalize and adapt therapeutic strategies and to improve diagnosis and tailor treatment.
Journal ArticleDOI
Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group.
Thomas J. Ettrich,Andreas Berger,Lukas Perkhofer,Severin Daum,Alexander König,Andreas Dickhut,Uwe A. Wittel,Kai Wille,Michael Geissler,Hana Algül,Eike Gallmeier,Jens Atzpodien,Marko Kornmann,Rainer Muche,Nicole Prasnikar,Andrea Tannapfel,Anke Reinacher-Schick,Waldemar Uhl,Thomas Seufferlein +18 more
TL;DR: The NEONAX trial addresses the question of the role of intensified perioperative treatment with nab-paclitaxel plus gemcitabine in resectable pancreatic cancers to improve disease-free survival and offers a unique potential for translational research.